Rethinking the Standard: Is a Chemotherapy-Free Future Possible for HER2-Enriched Breast Cancer?
The WSG-KEYRICHED-1 trial investigates a chemotherapy-free regimen for HER2-enriched early breast cancer, showing that 47% of patients achieved a pathological complete response using only immunotherapy and dual HER2 blockade.

















